A two-year clinical trial published in JAMA Cardiology found that vitamin K2 in the form of menaquinone-7 (MK-7) slowed the progression of coronary artery calcification in patients with existing heart disease, according to the study. The trial involved 180 patients at two Dutch hospitals and was conducted from 2012 to 2022. Patients taking 360 micrograms of MK-7 daily saw their calcium scores increase by about 19 units less per year than the placebo group, representing an approximately 9 percent slowing over the two years. Researchers and independent cardiologists said the effect was modest and that larger studies are needed to…

Newswire

Features

The Latest